<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIRITHROMYCIN</span><br/>(dir-ith-roe-my'sin)<br/><span class="topboxtradename">Dynabac<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">macrolide antibiotic</span><br/><b>Prototype: </b>Erythromycin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg enteric tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Dirithromycin is an analog of erythromycin. It binds reversibly to the 235 component of the 50-S ribosomal subunit of the
         bacteria, thus inhibiting RNA-dependent protein synthesis in bacterial cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is more active against gram-positive organisms than gram-negative organisms, including <i>Legionella, Helicobacter pylori,</i> and <i>Chlamydia trachomatis</i>. It is not effective against <i>Pseudomonas</i> or methicillin-resistant <i>Staphylococcus aureus (MRSA), S. epidermidis, Listeria monocytogenes, Legionella pneumophila, Haemophilus influenzae,</i> or <i>Neisseria gonorrhoeae.</i>
</p>
<h1><a name="uses">Uses</a></h1>
<p>Acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated
         skin/skin structure infections due to susceptible bacteria.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to dirithromycin, erythromycin, or any other macrolide antibiotic; known or suspected bacteremias.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment, pregnancy (category C). Safety and effectiveness in lactation or children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Bacterial Infections</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> 500 mg once/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or within 1 h of eating.</li>
<li>Do not cut, crush, or chew tablets.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, asthenia. <span class="typehead">CV:</span> Chest pain. <span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain, nausea, diarrhea, vomiting, dyspepsia, flatulence;</span> elevated liver function tests (ALT, AST, GGT). <span class="typehead">Skin:</span> Rash, urticaria. <span class="typehead">Respiratory:</span> Dyspnea, asthma-like symptoms, rhinitis, pharyngitis, increased coughing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>theophylline</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 6090% hydrolyzed to active metabolite, erythromycylamine, within 35 min. <span class="typehead">Peak:</span> 1.5 h. <span class="typehead">Distribution:</span> High tissue concentrations of active metabolite; slowly released back into the circulation. <span class="typehead">Metabolism:</span> Rapidly converted to active metabolite, erythromycylamine, in absorption and distribution phases. <span class="typehead">Elimination:</span> 8197% excreted in bile and feces. <span class="typehead">Half-Life:</span> 2050 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Take history of previous hypersensitivity to other macrolides (e.g., erythromycin) prior to initiation of therapy.</li>
<li>Withhold drug and notify physician if signs and symptoms of hypersensitivity occur (see Appendix F).</li>
<li>Monitor liver and renal function in patients with mild liver or renal impairment.</li>
<li>Monitor for S&amp;S of superinfection (see Appendix F).</li>
<li>Monitor theophylline levels if given concurrently with dirithromycin.</li>
<li>
            							Note: Dirithromycin may increase the blood level of theophylline, necessitating theophylline dosage adjustment.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take tablets whole and within 1 h of meals.</li>
<li>Monitor for and report S&amp;S of superinfection or pseudomembranous enterocolitis (see Appendix F).</li>
<li>Report any worsening of signs and symptoms of infection.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>